Analysts Rally Behind Merus (MRUS) After Cancer Treatment Breakthrough
Merus N.V. (MRUS) has captured Wall Street’s attention with groundbreaking Phase 2 trial results for its petosemtamab combination therapy. The treatment demonstrated a 79% survival rate in head and neck cancer patients, prompting a wave of analyst upgrades.
Sixteen analysts now maintain a consensus ’Buy’ rating, with price targets ranging from $75 to $110. BofA took the most aggressive stance, raising its target to $92 from $70. The average price target stands at $86, representing significant upside from the stock’s $55.14 opening price.
While recent earnings missed estimates, the company beat revenue expectations with $26.49 million. Market capitalization currently sits at $3.82 billion, with shares approaching their year-to-date high of $61.28.
